dar-202110260000916540false00009165402021-10-262021-10-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| | | | | | | | | | | | | | |
Date of report (Date of earliest event reported) | October 26, 2021 |
| | | | | | | | | | | | | | |
DARLING INGREDIENTS INC. |
| (Exact Name of Registrant as Specified in Charter) |
| | | | | | | | |
| Delaware | 001-13323 | 36-2495346 |
(State or Other Jurisdiction
of Incorporation) | (Commission
File Number) | (IRS Employer
Identification No.) |
5601 N. MacArthur Blvd., Irving, Texas 75038
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (972) 717-0300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | | | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | | | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | | | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock $0.01 par value per share | DAR | New York Stock Exchange | (“NYSE”) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 26, 2021, the Board of Directors (the “Board”) of Darling Ingredients Inc. (the “Company”) elected Celeste A. Clark, Ph.D., to the Board effective immediately. In connection with Dr. Clark’s election to the Board, the size of the Board was increased to ten members. It is expected that she will also be appointed to a new, standalone environmental, social and governance (ESG) committee currently being developed by the Board. The Board has determined that Dr. Clark is an independent director under the applicable New York Stock Exchange listing standards and the Company’s Corporate Governance Guidelines.
In connection with her service as a director, Dr. Clark will receive the Company’s standard non-employee director compensation, which currently consists of an annual retainer equal to $95,000, paid in quarterly installments, and an annual grant of $135,000 in value of restricted stock units, with Dr. Clark to receive a prorated amount of such grant, with the number of restricted stock units granted to be based on the closing price of our common stock on the date of her appointment to the Board. In addition, the Company will enter into its standard form of Indemnification Agreement for directors and executive officers with Dr. Clark, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2008, and is incorporated herein by reference.
There is no arrangement or understanding between Dr. Clark and any other persons pursuant to which she was selected as a director, nor are there any transactions in which Dr. Clark has an interest requiring disclosure under Item 404(a) of Regulation S-K.
A copy of the press release announcing Dr. Clark’s election to the Board is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| | | | | | | | |
| 99.1 | | | |
| 104 | | | Cover Page Interactive Data File (embedded within Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
| | DARLING INGREDIENTS INC. | |
| | | | |
| Date: October 27, 2021 | By: | /s/ John F. Sterling | |
| | | John F. Sterling | |
| | | Executive Vice President,
General Counsel | |